© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics adds Ventana ALK (D5F3) to Biomarker Test Menu

January 26, 2017


Helomics has added the Ventana ALK (D5F3) CDx Assay to its test menu and becomes one of only three sites offering the assay in the United States.


Visit: https://usinfo.roche.com/alk for more information.


The Ventana ALK (D5F3) CDx Assay is an FDA approved test which functions as a companion diagnostic to aid in the identification of ALK positive lung cancer patients who are eligible for treatment with Pfizer’s FDA approved therapy XALKORI® (crizotinib).  Lung cancer remains the leading cause of cancer deaths, representing 12.9% of all new cancer cases and 1.6 million deaths worldwide.  For a subset of non-small cell lung cancer patients, the use of this assay represents an opportunity to initiate targeted therapy.


“The addition of the Ventana ALK (D5F3) CDx Assay to our biomarkers platform bolsters our mission of offering testing modalities to drive personalized care.   Being one of three testing sites in the United States highlights our commitment to being on the cutting edge of new opportunities to support all patients affected by a cancer diagnosis.” – Arlette H. Uihlein, MD, FCAP, FASCP, Vice President, Pathology Services & Medical Director.


About the test:


The Ventana ALK (D5F3) CDx Assay is intended for laboratory use in the detection of the anaplastic lymphoma kinase (ALK) protein in formalin fixed paraffin embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with the Ventana Benchmark XT and Ventana BenchMark ULTRA Immunohistochemical (IHC) automated slide stainers. 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

Please reload

Recent Posts